Artificial intelligence has long been hailed as a revolution in drug development, but proof of its clinical impact has been limited—until now.

On June 3, 2025, researchers from Peking Union Medical College Hospital and AI drug developer Insilico Medicine published phase 2a trial data for Rentosertib, a small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), in Nature Medicine. This milestone makes Rentosertib the world’s fastest AI-discovered drug to reach this stage of clinical testing (Xu et al., 2025; Global Times, 2025).

A Closer Look at Rentosertib

Rentosertib (formerly ISM001-055) was developed using generative AI, which not only designed the molecule but also identified its novel target, TNIK—a kinase implicated in the fibrotic and inflammatory pathways of idiopathic pulmonary fibrosis (IPF).

IPF is a chronic, progressive lung disease marked by the irreversible scarring (fibrosis) of lung tissue. It leads to a steady decline in lung function, breathlessness, persistent coughing, and reduced oxygen intake. Affecting an estimated 5 million people globally, IPF has a median survival rate of just 3 to 4 years after diagnosis (Xu et al., 2025; Global Times, 2025).

Current treatments—such as pirfenidone and nintedanib—can slow progression but cannot halt or reverse the disease. Rentosertib, as a first-in-class TNIK inhibitor, represents a new therapeutic approach that may not only slow fibrosis but potentially improve lung function.

What Happened in the Phase 2a Trial?

The phase 2a trial tested Rentosertib in 71 patients with IPF across multiple medical centers. The study was carefully designed to ensure reliability: it was randomized (patients were assigned to groups by chance), double-blind (neither the patients nor the doctors knew who was receiving the drug), and placebo-controlled (one group received a non-active treatment to serve as a comparison).

Patients were divided into four groups:

  • One group received 30 mg of Rentosertib once daily (QD)
  • A second group received 30 mg twice daily (BID)
  • A third group received a higher dose of 60 mg once daily
  • The fourth group received a placebo

The main goal was to assess safety and tolerability—in other words, to see how well patients handled the drug and whether it caused any serious side effects.

The results were encouraging:

  • The 60 mg once-daily group showed the most promising response, with an average increase in lung function (measured by forced vital capacity, or FVC) of +98.4 mL.
  • By contrast, patients in the placebo group experienced a decline of −20.3 mL.
  • Side effects (called treatment-emergent adverse events, or TEAEs) were relatively mild and occurred at similar rates across all groups (Xu et al., 2025).

Why This Matters: AI’s Real-World Clinical Impact

Until now, AI-discovered drugs had not progressed beyond phase 1 trials. Rentosertib’s advancement into phase 2a—with published human safety and efficacy data—is a watershed moment for the field.

According to Chen Jing, VP at China’s Technology and Strategy Research Institute:

“AI has already made major breakthroughs in drug-related fields… With ongoing data accumulation and training, large-scale application and major results are only a matter of time”
(Global Times, 2025).

The case also highlights AI’s potential in identifying novel, previously overlooked targets, making discovery more efficient and intentional.

Challenges and Opportunities Ahead

While Rentosertib’s success is a promising sign, experts caution that AI in drug development still faces:

  • Limited access to diverse, high-quality biomedical data
  • High computational costs
  • Poor model interpretability
  • Evolving regulatory and intellectual property frameworks
    (Global Times, 2025)

Yet, these challenges also highlight where expertise and leadership are urgently needed. As AI continues to shape how therapies are discovered and developed, professionals across the pharmaceutical industry must be prepared to bridge technical innovation with scientific, ethical, and regulatory rigor.

Implications for GMDP Professionals

For regulatory affairs professionals, clinical scientists, and medical affairs leaders, this development emphasizes the growing need for cross-functional fluency in AI-driven development. It impacts:

  • Clinical trial design – AI can guide protocol optimization and patient selection.
  • Regulatory strategy – Agencies will increasingly expect technical justifications for AI-informed decisions.
  • Medical affairs – Explaining novel mechanisms like TNIK targeting will require deeper scientific literacy.

GMDP Academy supports this evolution with flexible, module-based professional development in areas like regulatory innovation, digital health, and strategic medical affairs.

Staying Ahead: GMDP Academy’s Module 8

Rentosertib’s development and trial success underscore the growing influence of AI, real-world data, and digital transformation in the pharmaceutical sector. To help professionals stay ahead, GMDP Academy offers Module 8: Digital Technology in Medicines Development.

This fully online module explores how digital technologies—from AI and big data to patient-centered tools and real-world evidence—are reshaping every stage of the development lifecycle. Taught by leading professionals in digital health and pharmaceutical innovation, it combines expert-led webinars, interactive discussions, and flexible scheduling to help participants meaningfully integrate digital tools into their work.

Join a global network of innovators and lead the digital transformation.

 📥 Download the Module 8 flyer 

📝 Apply Now

References

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred